Overview
Cancer screening firm's Q4 revenue rose 23%, beating analyst expectations
Adjusted EBITDA for Q4 was $63 mln, affected by $75 mln R&D expense
Outlook
Exact Sciences anticipates momentum from core products and portfolio expansion
Exact Sciences' merger with Abbott expected to close in Q2 2026
Result Drivers
SCREENING REVENUE - Screening revenue increased 26% to $695 mln, driven by Cologuard tests and PreventionGenetics
PRECISION ONCOLOGY - Precision Oncology revenue rose 14% to $183 mln, supported by Oncotype DX and therapy selection tests
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Beat | $878.38 mln | $860.90 mln (21 Analysts) |
Q4 Net Income | -$85.96 mln | ||
Q4 Basic EPS | -$0.45 | ||
Q4 Income From Operations | -$82.6 mln | ||
Q4 Pretax Profit | -$85.08 mln |
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 20 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Exact Sciences Corp is $105.00, about 1.7% above its February 12 closing price of $103.23
The stock recently traded at 315 times the next 12-month earnings vs. a P/E of 270 three months ago
Press Release: ID:nBw9FlpYDa
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)